Answers are grounded in this paper and cite their sources.
Prostate cancer remains a major global health burden, and metastatic castration-resistant prostate cancer remains incurable despite advances in systemic therapy. Gene and RNA therapeutics offer opportunities to target mechanisms that are difficult to modulate conventionally, but their translation is limited by delivery. Dendrimers are highly branched, generation-defined macromolecules that can condense and protect nucleic acids and be engineered with targeting ligands, steric stabilizers and stimuli-responsive components. This review critically evaluates dendrimer-based gene therapy for prostate cancer through an evidence-to-translation framework that separates direct therapeutic, platform and contextual evidence, while drawing selectively on the broader dendrimer literature to inform mechanism, design and translation. PAMAM and diaminobutyric poly(propylene imine) dendrimers dominate the field, with peptide dendrimers, dendrimersomes and hybrid nanomaterials expanding the design space. Reported therapeutic cargoes include siRNAs targeting Hsp27, BIRC5/survivin, cofilin-1 and MCL-1, plasmid-encoded MEG3, and cytokine-encoding plasmids. Although active targeting and systemic delivery have produced encouraging preclinical efficacy, major barriers remain, including serum instability, inefficient intracellular unpacking, limited biodistribution and pharmacokinetic data, cationic toxicity, and inadequate repeat-dose safety studies. Future progress will require biodegradable or ionizable architectures, clinically relevant metastatic models, biomarker-informed targeting, functional biodistribution, and scalable manufacturing.
No takes yet. Share an insight, caveat, or question.
Kasurka et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: